GlobeNewswire

The Connecticut Institute for Refugees and Immigrants honors Ethan Allen’s Farooq Kathwari

Del

DANBURY, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- The Connecticut Institute for Refugees and Immigrants (CIRI) honored Farooq Kathwari, Chairman, President and CEO of Danbury-based Ethan Allen Interiors Inc., with its Legacy Award at a gala dinner in Westport, CT., on September 23.

He was chosen for this honor in recognition of his commitment to humanitarian causes, to justice and human dignity, and to the plight of displaced people across the world. Mr. Kathwari has served in numerous capacities at many nonprofit organizations; among them, he is currently a member of the Board of Overseers of the International Rescue Committee, and a chairman emeritus of Refugees International.

The gala commemorated CIRI's 100 years as the state’s leading champion for refugees, immigrants, survivors of torture, and survivors of human trafficking. Founded in 1918 as the International Institute of Connecticut (IICONN), CIRI remains the state’s preeminent provider of advocacy and high-impact services that empower new Americans to thrive in Connecticut.

Claudia Connor, CIRI CEO and President, said, “Because we believe most Americans value the contributions that immigrants and refugees make to our nation, we continue to fight for their rights in a difficult political climate. Our mission is to provide comprehensive and compassionate legal and social services for vulnerable foreign-born residents of Connecticut. This mission has never been more essential than it is now.”

Ms. Connor continued, “Our gala honoree, Farooq Kathwari, symbolizes the many ways in which foreign-born Americans have helped build our country. As a respected business leader, he has grown Ethan Allen into a leading furniture and design company that employs more than 5,000 people in Connecticut and North America. He embodies the American dream of building a better life for his family and community and has given back many times over through his nonprofit and charitable work.”

Mr. Kathwari said, “I am proud to support the valuable work that CIRI does for immigrant and refugee communities in Connecticut. As an immigrant myself, I know that everyone who comes to America has the opportunity to contribute and enrich his or her new home.  But no one can succeed alone. CIRI provides the necessary services that new Americans need to start down the path to success.”

Mr. Kathwari’s family foundation, is the CIRI Centennial Partner for the gala. Other event sponsors include People’s United Bank, Praxair, Synchrony Financial, RBC Wealth Management, and Nuovo Pasta Productions.

Mr. Kathwari emigrated to the United States in 1965. He joined Ethan Allen in 1980, when it acquired KEA International, a company he formed in 1973 in partnership with Ethan Allen. Kathwari quickly rose through the ranks and became president in 1985 and board chair and chief executive officer in 1988. He has overseen the transformation of Ethan Allen, making it a quintessential American brand with a wide-reaching global presence, emphasizing quality, craftsmanship, diversity of styles, and environmental excellence as hallmarks of the brand.

Mr. Kathwari is an active humanitarian and peacemaker. In addition to his work at International Rescue Committee and Refugees International, he is a member of the advisory board of the Center for Strategic and International Studies; a member of the Council on Foreign Relations; chairman emeritus of Refugees International; a director of the Institute for the Study of Diplomacy at Georgetown University; co-chairman of the Muslim-Jewish Advisory Council; and a member of the International Advisory Council of the United States Institute of Peace. He is the founder of the Kashmir Study Group, and he served as a member of the President’s Advisory Commission on Asian Americans and Pacific Islanders from 2010 to 2014. Among his recognitions, Mr. Kathwari is a recipient of the 2018 Ellis Island Medal of Honor and has been recognized as an Outstanding American by Choice by the U.S. government. For more information visit www.farooqkathwari.com.

MEDIA CONTACT:
Geri Moran
Ethan Allen Global, Inc.
geri.moran@ethanallen.com
203.743.8374

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders17.6.2019 12:55:00 CESTPressemelding

BROOKFIELD, NEWS, June 17, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX: BAM.A, NYSE: BAM, Euronext: BAMA) today announced that at the company’s annual and special meeting of shareholders held on June 14, 2019 in Toronto, over 85% of Class A Limited Voting Shares (“Class A Shares”) voted in favour of a new management share option plan. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares (“Class B Shares”) were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 731,503,129 99.60 2,926,448 0.40 Angela F. Braly 730,750,957 99.50 3,67

VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®17.6.2019 12:00:00 CESTPressemelding

Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3rd vaccination of Sci-B-Vac® vs. Engerix-B® were statistically significantly higher in key subgroup analyses of adults age ≥ 18 years No safety signals observed – safety and tolerability consistent with known profile of the vaccine With positive PROTECT data, pending successful completion of CONSTANT study, submissions of BLA/MAA for approval in U.S., Europe, and Canada expected to begin mid-year 2020 VBI to host conference call and webcast today, Monday, June 17, 2019 at 8:00 AM ET CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive top-line results from the randomized, double-blind, pivotal Phase 3 study, PROTECT, designed to

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CESTPressemelding

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle